Inhibrx Inc Stock price
Compare with Peer Group
Is Inhibrx Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 9,120 stocks worldwide.
Key metrics
Inhibrx Inc Stock Analysis
Analyst Opinions
10 Analysts have issued a Inhibrx Inc forecast:
Analyst Opinions
10 Analysts have issued a Inhibrx Inc forecast:
Don't miss a Thing! We will send you all news about Inhibrx Inc directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Inhibrx Inc Stock News
Company Profile
Inhibrx, Inc. engages in researching and developing biotechnology. It is a clinical stage company, which focuses on developing pipeline of novel biologic therapeutic candidates. The firm’s pipeline is focused on oncology, orphan diseases and infectious diseases. It utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary sdAb platform. The company was founded by Mark Paul Lappe, Quinn Deveraux and Brendan P. Eckelman in April 2010 and is headquartered La Jolla, CA.
| Head office | United States |
| CEO | Mr. Lappe |
| Employees | 110 |
| Founded | 2010 |
| Website | inhibrx.com |


